Trial Profile
An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners ("Home Injection Group") or administered by healthcare professionals.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Ipsen
- 06 Dec 2013 Planned number of patients changed from 30 to 25 as reported by Australian New Zealand Clinical Trials Registry record.
- 06 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
- 06 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.